Literature DB >> 11837758

The role of glucocorticoid pulse therapy in pulmonary involvement in leptospirosis.

S V Trivedi1, R K Chavda, P Z Wadia, V Sheth, P N Bhagade, S P Trivedi, A M Clerk, D M Mevawala.   

Abstract

OBJECTIVES: This study discusses incidence and clinical profile of pulmonary involvement in leptospirosis in South Gujarat. It also tries to evaluate the effect of high dose glucocorticoid pulse therapy (GPT) on it.
METHOD: A study was carried out on hundred and two patients of suspected leptospirosis, referred to Government Medical College, New Civil Hospital, Surat between June 99 to September 99. The incidence, clinical profile, and specific investigations were studied in patients having pulmonary involvement. Some of the patients were given high dose glucocorticoid pulse therapy. Their outcomes were compared with those who had not been given glucocorticoid pulse therapy.
RESULTS: Out of seventy seven seropositive patients 13 (16.8%) developed pulmonary involvement. Mortality was two out of eight patients in the group that received GPT and four out of five patients in the group that did not receive GPT. Two patients who died in the steroid treated group received the drug after 12 hours of onset of dyspnea.
CONCLUSIONS: High dose GPT should be given as early as possible after the onset of dyspnea to all the patients with pulmonary involvement in leptospirosis. Further studies are required to establish the GPT as a standard regimen in treatment of pulmonary involvement in leptospirosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11837758

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  11 in total

1.  Pulmonary leptospirosis: an excellent response to bolus methylprednisolone.

Authors:  V V Shenoy; V S Nagar; A A Chowdhury; P S Bhalgat; N I Juvale
Journal:  Postgrad Med J       Date:  2006-09       Impact factor: 2.401

2.  Leptospirosis: The "mysterious" mimic.

Authors:  Ricardo Izurieta; Sagar Galwankar; Angela Clem
Journal:  J Emerg Trauma Shock       Date:  2008-01

3.  Cyclophosphamide in pulmonary alveolar hemorrhage due to leptospirosis.

Authors:  Samir V Trivedi; Ashwin H Vasava; Tinkal C Patel; Lovleen C Bhatia
Journal:  Indian J Crit Care Med       Date:  2009 Apr-Jun

4.  Severe Pulmonary Involvement in Leptospirosis: Alternate antibiotics and systemic steroids.

Authors:  B Jayakrishnan; Fatma Ben Abid; Abdullah Balkhair; Juma K Alkaabi; Omar A Al-Rawas; Jojy George; Khalfan Al-Zeedy
Journal:  Sultan Qaboos Univ Med J       Date:  2013-05-09

5.  Randomized controlled trial of pulse methyl prednisolone × placebo in treatment of pulmonary involvement associated with severe leptospirosis. [ISRCTN74625030].

Authors:  Ana Flávia C Azevedo; Demócrito de B Miranda-Filho; Gustavo T Henriques-Filho; Alfredo Leite; Ricardo A A Ximenes
Journal:  BMC Infect Dis       Date:  2011-06-30       Impact factor: 3.090

6.  A rare case of leptospirosis with isolated lung involvement.

Authors:  Vijay Kumar Agrawal; Abhishek Bansal; Meenu Pujani
Journal:  Indian J Crit Care Med       Date:  2015-03

7.  Clinical spectrum of severe leptospirosis in the UK.

Authors:  Venkat Sivaprakasam; Wendy J Zochowski; Martin F Palmer
Journal:  JMM Case Rep       Date:  2014-12-01

8.  Pulmonary manifestations of leptospirosis.

Authors:  Sameer Gulati; Anu Gulati
Journal:  Lung India       Date:  2012-10

Review 9.  Leptospirosis among the self-supporting convicts of Andaman Island during the 1920s--the first report on pulmonary haemorrhage in leptospirosis?

Authors:  P Vijayachari; A P Sugunan; S S Singh; P P Mathur
Journal:  Indian J Med Res       Date:  2015-07       Impact factor: 2.375

10.  Severe leptospirosis in tropical Australia: Optimising intensive care unit management to reduce mortality.

Authors:  Simon Smith; Yu-Hsuan Liu; Angus Carter; Brendan J Kennedy; Alexis Dermedgoglou; Suzanne S Poulgrain; Matthew P Paavola; Tarryn L Minto; Michael Luc; Josh Hanson
Journal:  PLoS Negl Trop Dis       Date:  2019-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.